Comparison of Harpoon Therapeutics Inc. (HARP) and Emmaus Life Sciences Inc. (OTCMKTS:EMMA)

Since Harpoon Therapeutics Inc. (NASDAQ:HARP) and Emmaus Life Sciences Inc. (OTCMKTS:EMMA) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harpoon Therapeutics Inc. 17 0.00 9.98M -2.10 0.00
Emmaus Life Sciences Inc. 2 0.00 29.67M -1.05 0.00

Demonstrates Harpoon Therapeutics Inc. and Emmaus Life Sciences Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 has Harpoon Therapeutics Inc. and Emmaus Life Sciences Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Harpoon Therapeutics Inc. 59,796,285.20% -65.9% -35.9%
Emmaus Life Sciences Inc. 1,477,001,194.74% 0% 0%

Analyst Recommendations

In next table is given Harpoon Therapeutics Inc. and Emmaus Life Sciences Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Harpoon Therapeutics Inc. 0 0 3 3.00
Emmaus Life Sciences Inc. 0 0 0 0.00

Harpoon Therapeutics Inc. has an average price target of $25, and a 69.38% upside potential.

Insider and Institutional Ownership

Harpoon Therapeutics Inc. and Emmaus Life Sciences Inc. has shares owned by institutional investors as follows: 58.2% and 0%. About 0.2% of Harpoon Therapeutics Inc.’s share are owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Harpoon Therapeutics Inc. 1.23% 41.69% 27.56% 55.93% 0% 40.22%
Emmaus Life Sciences Inc. -19.15% -35.59% -57.68% -75.45% -75.64% -56.74%

For the past year Harpoon Therapeutics Inc. had bullish trend while Emmaus Life Sciences Inc. had bearish trend.

Summary

Emmaus Life Sciences Inc. beats on 6 of the 10 factors Harpoon Therapeutics Inc.